WaveMan · Form 4
RA Capital Healthcare Fund LP insider trades
> Search tickers & screens ⌘K
LIVE

RA Capital Healthcare Fund LP insider trades

RA Capital Healthcare Fund LP has filed 46 Form 4s with the SEC that we hold, for Acrivon Therapeutics, Inc. (ACRV) (Director, 10% owner), Tyra Biosciences, Inc. (TYRA) (Director, 10% owner), CDTX (Director, 10% owner) and Climb Bio, Inc. (CLYM) (Director, 10% owner), among 25 companies in all. Across all of them we count 28 purchases worth $219.3M and 5 sales worth $62.2M reported on Form 4. In the last 12 months: 11 purchases ($61.9M) and 3 sales ($58.4M). The largest single trade was a purchase of 3,441,966 shares of SpyGlass Pharma, Inc. worth $55.1M, dated 2026-02-09. The first filing on our record is dated 2022-03-16 and the latest 2026-06-11.

Acrivon Therapeutics, Inc. (ACRV)

Director, 10% owner · 4 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2022-11-17P, purchase reported on Form 43,389,500$42.4M2022-11-21

Tyra Biosciences, Inc. (TYRA)

Director, 10% owner · 4 filings · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2024-11-08P, purchase reported on Form 41,220,681$19.8M2024-11-13
2025-06-09P, purchase reported on Form 4186,850$1.9M2025-06-11

CDTX

Director, 10% owner · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Climb Bio, Inc. (CLYM)

Director, 10% owner · 3 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2026-01-05P, purchase reported on Form 47,111$24.9K2026-01-07

Janux Therapeutics, Inc. (JANX)

Director, 10% owner · 3 filings · 4 purchases and sales
Trade dateCodeSharesValue as filedFiled
2025-03-05P, purchase reported on Form 4304,287$9.3M2025-03-07
2025-03-05P, purchase reported on Form 437,455$1.2M2025-03-07
2025-03-06P, purchase reported on Form 4372,093$11.5M2025-03-07
2025-03-07P, purchase reported on Form 4110,206$3.4M2025-03-07

Nkarta, Inc. (NKTX)

Director, 10% owner · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Wave Life Sciences, Inc. (WVE)

Director, 10% owner · 3 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2022-06-16P, purchase reported on Form 49,480,052$20.4M2022-06-21

ARS Pharmaceuticals, Inc. (SPRY)

Director, 10% owner · 2 filings · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-09-21P, purchase reported on Form 4191,309$732.7K2023-09-25
2023-09-21P, purchase reported on Form 42,508,691$7.5M2023-09-25

Acumen Pharmaceuticals, Inc. (ABOS)

Director, 10% owner · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

ETNB

Director, 10% owner · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Fulcrum Therapeutics, Inc. (FULC)

10% owner · 2 filings · 5 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-01-04P, purchase reported on Form 458,369$455.3K2023-01-06
2023-01-04P, purchase reported on Form 4122,334$860.0K2023-01-06
2025-12-08S, sale reported on Form 41,377,020$18.4M2025-12-10
2025-12-08S, sale reported on Form 491,722$1.4M2025-12-10
2025-12-08S, sale reported on Form 42,706,397$38.6M2025-12-10

ICVX

Director, 10% owner · 2 filings · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-03-28P, purchase reported on Form 4175,318$794.2K2022-03-30
2022-03-29P, purchase reported on Form 48,900$42.3K2022-03-30

AN2 Therapeutics, Inc. (ANTX)

10% owner · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2024-08-09S, sale reported on Form 4114,759$123.9K2024-08-13
2024-08-09S, sale reported on Form 43,410,335$3.7M2024-08-13

Adicet Bio, Inc. (ACET)

10% owner · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-02-18P, purchase reported on Form 474,577$525.0K2026-04-13
2026-02-19P, purchase reported on Form 474,268$535.5K2026-04-13
2026-02-20P, purchase reported on Form 474,751$543.4K2026-04-13

Cytek Biosciences, Inc. (CTKB)

Director, 10% owner · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-03-14P, purchase reported on Form 4342,143$4.2M2022-03-16
2022-03-15P, purchase reported on Form 4241,727$3.0M2022-03-16

DICE

Reporting owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Evommune, Inc. (EVMN)

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Hemab Therapeutics Holdings, Inc. (COAG)

10% owner · 1 filing · 5 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-05-07P, purchase reported on Form 41,985$49.5K2026-05-11
2026-05-07P, purchase reported on Form 47,921$192.8K2026-05-11
2026-05-08P, purchase reported on Form 41,483$37.0K2026-05-11
2026-05-11P, purchase reported on Form 425,720$643.0K2026-05-11
2026-05-11P, purchase reported on Form 414,149$346.2K2026-05-11

ITOS

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

LENZ Therapeutics, Inc. (LENZ)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Mineralys Therapeutics, Inc. (MLYS)

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Parabilis Medicines, Inc. (PBLS)

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

PepGen Inc. (PEPG)

Director, 10% owner · 1 filing · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2025-09-26P, purchase reported on Form 49,375,000$30.0M2025-09-30

Septerna, Inc. (SEPN)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

SpyGlass Pharma, Inc. (SGP)

Director, 10% owner · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2026-02-09P, purchase reported on Form 4248,034$4.0M2026-02-11
2026-02-09P, purchase reported on Form 43,441,966$55.1M2026-02-11
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1315082) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms